All In Biotech

Drug Trial Radar · NCT07229638

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

An Open-label, Multicenter Phase IB/II Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Apr 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • SHR-9839(sc) For InjectionDrug

    SHR-9839(sc) for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLT)Time frame: 28 days.
  2. Adverse events (AEs)Time frame: 13 months.
  3. Recommended dose for expansion (RDE)Time frame: From the first dose to the last visit, about 13 months.
  4. Objective Response Rate (ORR)Time frame: From the first dose to the last visit, about 13 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Fudan University Affiliated Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.